, the most common extracranial malignancy in childhood. However, the mechanisms underlying HPSE expression in NB still remain largely unknown. Herein, through analyzing cis-regulatory elements and mining public microarray datasets, we identified SMAD family member 4 (Smad4) as a crucial transcription regulator of HPSE in NB. We demonstrated that Smad4 repressed the HPSE expression at the transcriptional levels in NB cells. Mechanistically, Smad4 suppressed the HPSE expression through directly binding to its promoter and repressing the lymphoid enhancer binding factor 1 (LEF1)-facilitated transcription of HPSE via physical interaction. Gain-and loss-of-function studies demonstrated that Smad4 inhibited the growth, invasion, metastasis, and angiogenesis of NB cells in vitro and in vivo. Restoration of HPSE expression prevented the NB cells from changes in these biological features induced by Smad4. In clinical NB specimens, Smad4 was under-expressed and inversely correlated with HPSE levels, while LEF1 was highly expressed and positively correlated with HPSE expression. Patients with high Smad4 expression, low LEF1 or HPSE levels had greater survival probability. These results demonstrate that Smad4 suppresses the tumorigenesis and aggressiveness of NB through repressing the HPSE expression.
Results
Smad4 represses the expression of HPSE in cultured NB cell lines. Mining the publicly available databases Genomatix 10 and R2: microarray analysis and visualization platform (http://r2.amc.nl) revealed three potential transcription factors correlated with HPSE expression in NB tissues, including Smad4, LEF1, and peroxisome proliferator-activated receptor gamma (PPARG) (Supplementary Fig. S1a ). However, transfection of short hairpin RNA (shRNA) specific for PPARG did not affect the HPSE promoter activity in NB cell lines ( Supplementary Fig. S1b ). Meanwhile, one Smad4 binding site and three LEF1 binding sites were noted within the HPSE promoter, locating at bases − 2287/− 2277, − 1435/− 1419, − 1351/− 1335, and − 571/− 555 relative to the transcription start site (TSS), respectively (Fig. 1a) . Notably, negative or positive correlation between HPSE and Smad4 or LEF1 expression was observed in different NB and neuroblastic tumor cohorts ( Supplementary Fig. S1c ). Lower Smad4 and higher HPSE levels were observed in NB cell lines than those in normal dorsal ganglia (DG; Fig. 1b) .
To investigate the effects of Smad4 on HPSE expression in NB cells, we performed the Smad4 over-expression and knockdown experiments. Western blot and real-time quantitative RT-PCR assays indicated that stable transfection of Smad4 into IMR32 and BE(2)-C cells obviously increased the expression of Smad4, and decreased the HPSE levels, than those of empty vector (mock)-transfected cells (Fig. 1c,d ). In contrast, transfection of shRNAs targeting Smad4 (sh-Smad4) into SH-SY5Y and SK-N-SH cells resulted in decreased protein and transcript levels of Smad4 and increased HPSE expression in NB cells, when compared to those stably transfected with scramble short hairpin RNA (sh-Scb) (Fig. 1e,f) . Nuclear run-on assay indicated that stable over-expression or knockdown of Smad4 decreased or increased the nascent transcript levels of HPSE in NB cells, respectively ( Supplementary  Fig. S2a ). In SH-SY5Y and SK-N-SH cells, administration of transforming growth factor beta (TGF-β ) resulted in increased activity of Smad4 response element reporter ( Supplementary Fig. S2b ) and decreased HPSE levels ( Fig. 1g and Supplementary Fig. S2c ), which were abolished by knockdown of Smad4 (Fig. 1g , Supplementary  Fig. S2b,c) . However, treatment of IMR32 and BE(2)-C cells with either TGF-β or inhibitor of its receptors (LY364947) 11 , did not affect the nuclear translocation of Smad4 and inhibition of HPSE expression induced by stable transfection of Smad4 ( Supplementary Fig. S3a,b) . Co-immunoprecipitation (Co-IP) and western blot assays indicated that transfection of D351H and R361H, two Smad4 constructs with mutation of the loop-helix region 12 , abolished the interaction of Smad4 with R-Smads, phosphorylated Smad1 and Smad2 (p-Smad1 and p-Smad2), in these NB cells ( Supplementary Fig. S3c ). In addition, transfection of D351H or R361H did not influence the expression levels and promoter activity of HPSE ( Supplementary Fig. S3d -f). Treatment with activin A-neutralizing antibody did not diminish the activation of Smad4 response element reporter in IMR32 and BE(2)-C cells stably transfected with Smad4 ( Supplementary Fig. S3g ). Instead, administration of LDN-193189, the inhibitor of bone morphogenetic protein (BMP) type I receptors 13 , abolished the increased activity of BMP/Smad transcriptional reporter induced by BMP-2 ( Supplementary Fig. S2h ). Moreover, LDN-193189 treatment also prevented the IMR32 and BE(2)-C cells from decrease in the expression of HPSE induced by stable transfection of Smad4 ( Fig. 1h and Supplementary Fig. S3i ). These results demonstrated that Smad4 considerably repressed the HPSE expression at the transcriptional levels in NB cells.
Smad4 represses the transcription of HPSE through direct binding to its promoter. To determine whether Smad4 could directly target its binding site, the HPSE promoter luciferase reporter vector and its truncates were transfected into NB cells stably transfected with empty vector (mock) or Smad4. Dual-luciferase assay indicated that − 3.5 to − 0.7 kb relative to TSS was essential for the negative control of HPSE promoter activity, and mutation of Smad4 binding site within this region resulted in increased HPSE promoter activity in cultured SH-SY5Y and SK-N-SH cells (Fig. 2a) . Ectopic expression or knockdown of Smad4 attenuated and enhanced the promoter activity of HPSE in NB cells, respectively (Fig. 2b,c) , and mutation of Smad4 binding site partially abolished these effects (Fig. 2b,c) . In addition, BMP-2 treatment facilitated the decreased HPSE promoter activity in IMR32 cells stably transfected with Smad4, which was abolished by administration of LDN-193189 (Fig. 2d) . Meanwhile, administration of TGF-β attenuated the increase in HPSE promoter activity induced by stable knockdown of Smad4 in SK-N-SH cells, and these effects were abolished by LY364947 treatment (Fig. 2d) . Chromatin immunoprecipitation (ChIP) and quantitative PCR (qPCR) assays were applied to measure the enrichment of Smad4 on HPSE promoter with three tiled primer sets. In cultured NB cells, enrichment of Smad4 was observed at the region (− 2347/− 2148) around its binding site (Fig. 2e) . As controls, no HPSE promoter regions were immunoprecipitated with unspecific antibody (isotype IgG) (Fig. 2e) . Stable transfection of Smad4 or sh-Smad4 into IMR32 and SK-N-SH cells resulted in increased and decreased binding of Smad4 to HPSE promoter, respectively (Fig. 2e ), which were abolished by treatment with LDN-193189 or TGF-β (Fig. 2e) . These results indicated that Smad4 directly interacted with the binding site within HPSE promoter to repress its transcription.
Smad4 represses the LEF1-facilitated transcription of HPSE in NB cells. Since previous studies indicate the interaction between Smad4 and LEF1 14, 15 , and combining above evidence showing the potential roles of LEF1 in HPSE expression, we further investigated the effects of Smad4 on LEF1-mediated HPSE expression. As shown in Fig. 3a ,b, Co-IP and immunofluorescence assays revealed the endogenous protein interaction between Smad4 and LEF1 in cultured NB cells. To determine the domain essential for this interaction, a series of Myc-tagged Smad4 truncates were co-transfected with FLAG-tagged LEF1 construct into NB cells, and the results indicated that the 511-552 amino acids of Smad4 was crucial for the interaction with LEF1 (Fig. 3c) . Dual-luciferase assay indicated that stable transfection of Smad4 attenuated the activity of T-cell factor (TCF)/LEF-responsive construct, and inhibited the LEF1-facilitated activity of HPSE promoter in IMR32 and BE(2)-C cells (Fig. 3d) . ChIP and qPCR assays revealed the endogenous enrichment of LEF1 on the − 673/− 476 bp region, but not the − 2347/− 2148 or − 1505/− 1268 bp region, of HPSE promoter (Fig. 3e) . Transfection of LEF1 increased the HPSE promoter activity in NB cells, while mutation of LEF1 binding site within − 673/− 476 bp region abolished these effects ( Supplementary Fig. S4a ). In addition, transfection of Smad4 prevented the increased enrichment of LEF1 on HPSE promoter induced by ectopic expression of LEF1 (Fig. 3e) . Dual-luciferase, nuclear run-on, real-time quantitative RT-PCR, and western blot assays further indicated that stable transfection of Smad4 prevented the NB cells from increased promoter activity and expression levels of HPSE induced by LEF1 over-expression ( Supplementary Fig. S4a, Fig. 3f-h ). These results indicated that Smad4 repressed the LEF1-facilitated HPSE transcription in NB cells.
Smad4 suppresses the growth, invasion, and angiogenesis of NB cells in vitro.
Since previous studies indicate that HPSE participates in the growth, invasion, and angiogenesis of cancer cells 16, 17 , and combining the evidence that Smad4 directly regulated the expression of HPSE, we investigated the effects of Smad4 over-expression and HPSE restoration on cultured NB cells. As shown in Fig. 4a ,b, transfection of HPSE increased the expression and activity of HPSE, and restored the decrease in HPSE expression and activity induced by Smad4 in IMR32 and BE(2)-C cells. In MTT colorimetric and soft agar assays, stable transfection of Smad4 suppressed the viability and anchorage-independent growth of NB cells, when compared to those stably transfected with empty vector (mock) (Fig. 4c,d ). In matrigel invasion assay, Smad4 over-expression decreased the invasion capability of IMR32 and BE(2)-C cells (Fig. 4e) . The tube formation of endothelial cells was decreased by treatment with the medium preconditioned by stable transfection of NB cells with Smad4 (Fig. 4f ). In addition, restoration of HPSE expression via transfection of HPSE vector prevented the NB cells from their decrease in growth, invasion, and angiogenesis induced by stable over-expression of Smad4 ( Fig. 4c-f ).
On the other hand, we investigated the effects of Smad4 on LEF1-mediated HPSE activity, growth, invasion, and angiogenesis of NB cells. As shown in Supplementary Fig. S4b , increased HPSE activity was observed in NB cells stably transfected with LEF1. In MTT colorimetric and soft agar assays, LEF1 over-expression promoted the viability and anchorage-independent growth of IMR32 and BE(2)-C cells, when compared to those stably transfected with mock ( Supplementary Fig. S4c,d ). Matrigel invasion assay showed that NB cells stably transfected with LEF1 presented an increased invasion capacity than mock-transfected cells ( Supplementary Fig. S4e ). The tube formation of endothelial cells was enhanced by treatment with the medium preconditioned by stable transfection of NB cells with LEF1 ( Supplementary Fig. S4f ). In addition, transfection of Smad4 rescued the IMR32 and BE(2)-C cells from their changes in HPSE activity, growth, invasion, and angiogenesis induced by ectopic expression of LEF1 ( Supplementary Fig. S4b-f ). Collectively, these results revealed the tumor suppressive roles of Smad4 in regulating the growth, invasion, and angiogenesis of NB cells.
Smad4 suppresses the growth, metastasis, and angiogenesis of NB cells in vivo .
We next investigated the efficacy of Smad4 over-expression against tumor growth, metastasis, and angiogenesis in vivo. Stable transfection of Smad4 into BE(2)-C cells resulted in decreased growth and tumor weight of subcutaneous xenograft tumors in athymic nude mice, when compared to those stably transfected with empty vector (mock; Fig. 5a ,b). In addition, stable transfection of Smad4 resulted in a decrease in CD31-positive mean vessel density within tumors (Fig. 5c ). In the experimental metastasis studies, BE(2)-C cells stably transfected with Smad4 established statistically fewer lung metastatic colonies and higher survival probability than mock group (Fig. 5d,e) . Restoration of HPSE expression abolished these changes induced by stable over-expression of Smad4 (Fig. 5a-e) . These results were consistent with the findings that Smad4 suppressed the growth, invasion, and angiogenesis of NB cells in vitro.
Smad4 and LEF1 are inversely or positively correlated with HPSE expression in NB tissues.
Mining the publicly available data derived from Oncogenomics (https://pob.abcc.ncifcrf. gov/cgi-bin/JK) and TARGET (https://target.nci.nih.gov/dataMatrix/) indicated no copy number loss and low mutation frequency of Smad4 gene in NB ( Supplementary Fig. S5a,b) . To investigate the expression of Smad4 and LEF1 in NB tissues, paraffin-embedded sections from 42 well-established primary cases were collected. Immunohistochemical staining revealed that Smad4 and LEF1 were expressed in the nuclei of tumor cells (Fig. 6a) . Smad4 expression was detected in 16/42 (38.1%) cases and the staining was weak in 8, moderate in 5, and intense in 3 (Supplementary Table S1 ). The Smad4 immunoreactivity was significantly lower in NB cases with poor differentiation (P < 0.001), higher mitosis karyorrhexis index (MKI) (P = 0.002), and advanced international neuroblastoma staging system (INSS) stages (P = 0.016) ( Supplementary Table S1 ). Notably, the immunostaining of HPSE was inversely or positively correlated with that of Smad4 (correlation coefficient R = − 0.583, P < 0.001) and LEF1 (correlation coefficient R = 0.553, P < 0.001) in NB cases, respectively ( Fig. 6a and Supplementary Table S2 ). Western blot and real-time quantitative RT-PCR were applied to measure the expression levels of Smad4, LEF1, and HPSE in 30 NB specimens and DG. As shown in Fig. 6b-d , lower Smad4 expression and higher LEF1 or HPSE levels were observed in NB tissues than those in DG, which was in line with the data derived from R2: microarray analysis and visualization platform ( Supplementary Fig. S5c ). In addition, lower Smad4 levels and higher expression of LEF1 or HPSE were observed in NB specimens with poorer differentiation (Fig. 6e) , advanced INSS Supplementary Fig. S5d ), or relapse ( Supplementary Fig. S5d ). There was an inverse correlation between Smad4 protein and HPSE transcript levels in NB tissues (correlation coefficient R = − 0.725, P < 0.001, Fig. 6f ), while LEF1 protein levels were positively correlated with HPSE transcript levels (correlation coefficient R = 0.734, Scientific RepoRts | 6:32628 | DOI: 10.1038/srep32628 P < 0.001, Fig. 6g ). Kaplan-Meier survival plots of 102 well-defined NB cases derived from R2 microarray analysis and visualization platform revealed that patients with high Smad4 expression (P = 3.8 × 10 −3 ), low LEF1 levels (P = 2.4 × 10 −4 ), or low HPSE expression (P = 3.4 × 10 −3 ) expression had greater survival probability (Fig. 6h) , which was further validated by different NB cohorts derived from R2 database (Supplementary Fig. S6 ). These results indicated that Smad4 and LEF1 were inversely or positively correlated with HPSE expression in NB tissues.
Discussion
Smad4, locating at chromosome 18q21, was first identified as a tumor suppressor gene in pancreatic cancer 18 . Subsequent studies show that Smad4 is involved in the TGF-β family signaling pathways 19 . The TGF-β family contains about 40 structurally related factors, including TGF-β , activin, inhibins, and BMPs, which exert signaling through binding to their receptors; upon receptor activation, the receptor-regulated Smads (R-Smads), including Smad1, Smad2, Smad3, Smad5 and Smad8, are phosphorylated to associate with the common Smad, Smad4, and mediate the nuclear translocation of heteromeric complex that regulates gene transcription 19, 20 . It has been indicated that Smad4 is down-regulated in many human cancers, as a result of mutation, homozygous deletion, and heterozygous loss 21 . Mutation of Smad4 gene occurs frequently in pancreatic 22 and colorectal cancer 23 . Transfection of Smad4 into pancreatic cancer cells reduces the anchorage-independent growth by more than 50%, and inhibits xenograft tumor growth 24 . In addition, stable over-expression of Smad4 in colon cancer cells suppresses their growth in vivo 25 . However, few mutation of Smad4 gene is seen in the rest of human cancers 26 . In the current study, we searched the publicly available databases Oncogenomics and TARGET, and found no copy number loss and low mutation frequency of Smad4 in NB. We demonstrated the down-regulation of Smad4 in NB tissues and cell lines. Low Smad4 expression was associated with poor prognosis of NB patients, suggesting that Smad4 may be a potential outcome predictor for NB. In addition, we found that ectopic expression of Smad4 suppressed the growth, invasion, metastasis, and angiogenesis of NB cells, suggesting the tumor suppressive roles of Smad4 in the progression of NB.
The heteromeric Smad complexes regulate target gene expression through direct binding to DNA, interaction with DNA-binding proteins, or recruitment of transcriptional co-activators or co-repressors 19 . Smad4 binds to the Smad-binding element, an 8-bp palindromic sequence (5′-GTCTAGAC-3′), for transcriptional regulation of TGF-β target genes 27 . Through targeting the promoter regions, Smad4 induces the expression of p15 ink4b to inhibit the growth of pancreatic cancer cells 24 . Enhanced Smad4 binding to the promoter of snail family zinc finger (Snail) contributes to its expression and epithelial-mesenchymal transition in skin carcinogenesis 28 . Over-expression of Smad4 induces the expression of p21 waf1 in breast cancer cells in the presence or absence of TGF-β stimulation, and Smad4 can bypass the TGF-β receptor activation to increase p21 waf1 levels in pancreatic cancer cells 29 . In addition, Smad4 positively regulates the c-Myc expression in a TGF-β -independent manner 12 . In this study, we demonstrated that HPSE was a novel transcriptional target gene of Smad4. Previous studies have shown the existence of TGF-β /Smad signaling in some NB cell lines. TGF-β treatment facilitates the nuclear localization of Smad2 in SK-N-SH cells 30 . Ectopic over-expression of TGF-β type II receptor suppresses the tumor-forming ability and induces differentiation in LAN5 cells 31 . However, TGF-β and its receptors are usually down-regulated in aggressive or advanced stage NB 32, 33 . Our findings indicated that TGF-β /Smad4 signaling was able to repress the HPSE expression in two non-MYCN amplified NB cells (SK-N-SH and SH-SY5Y), but not in MYCN amplified ones. In IMR32 and BE(2)-C cells, the Smad4-repressed HPSE expression was abolished by disruption of its interaction with p-Smad1 or p-Smad2, two R-Smads activated by BMP and activin receptors 19, 20 . Since administration of activin A-neutralizing antibody did not affect the activity of Smad4 response element reporter in these cells, we ruled out the possible involvement of activin A signaling. Instead, as a member of BMP family expressing mainly in the nervous system, BMP-2 activated the BMP/Smad transcriptional reporter and facilitated the down-regulation of HPSE induced by Smad4 in IMR32 and BE(2)-C cells, which were abolished by the inhibitor of BMP type I receptors. It has been indicated that BMP-2 induces the phosphorylation of Smad1/5/8 34 , and is capable of facilitating growth arrest and neuronal differentiation in NB cells 35 . We believe that both TGF-β -dependent and -independent R-Smad activation occurs in NB cells to regulate the Smad4-mediated repression of HPSE expression in a context-dependent manner.
Human HPSE gene is located at chromosome 4q21.3, and its expression is regulated at the transcriptional levels 36 . The HPSE promoter contains GC-rich sequences and lacks a typical TATA or CCAAT box 36 . Previous studies indicate that transcription factors specific protein 1 and ETS are associated with basal HPSE promoter activity in thyroid tumor cells 37 , while early growth response 1 is implicated in inducible transcription of HPSE gene in prostate cancer cells 38 . In glioblastoma, glioma-associated oncogene homolog 1 facilitates the transcription of HPSE to promote tumor angiogenesis and aggressive growth 39 . Nuclear factor κ B mediates the hypoxia-induced up-regulation of HPSE in pancreatic caner cells 40 . In addition, HPSE is induced in tumor cells by hepatocyte growth factor 41 , basic fibroblast growth factor 41 , and platelet-derived growth factor 41 . On the other hand, tumor suppressor p53 negatively regulates HPSE gene expression, suggesting that p53 gene mutation may contribute to increased HPSE expression in tumors 42 . Despite extensive studies on the regulation of HPSE expression during tumorigenesis, little is known about HPSE gene transcription in NB. In this study, we demonstrated that LEF1 facilitated the HPSE transcription via directly binding to its promoter. Previous studies indicate that LEF1 forms a complex with Smad4 to activate the promoter of msh homeobox 2 in murine embryonic stem cells 15 . However, in palate medial-edge epithelial cells, LEF1 is activated by forming a complex with Smad4 to bind with the E-cadherin promoter to repress its transcription 14 . Our evidence shows that Smad4 is able to interact with LEF1 to abolish its binding to proximal HPSE promoter region. Over-expression of Smad4 rescued the NB cells from LEF1-facilitated growth, invasion and angiogenesis, suggesting that Smad4 may exert its tumor suppressive functions, at least in part, through interacting and repressing the LEF1 activity in regulation of HPSE expression in NB.
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In summary, we have shown that Smad4 is down-regulated in NB tissues, and inhibits the growth, invasion, metastasis, and angiogenesis of NB cells in vitro and in vivo. Furthermore, Smad4 suppresses the expression of HPSE via targeting its binding site within the promoter and attenuating LEF1-faclitated transcription in NB cell lines. This study extends our knowledge about the regulation of HPSE at the transcriptional level by transcription factors, and suggests that Smad4 and LEF1 may be of potential values as novel therapeutic targets for human NB. Meanwhile, the roles and underlying mechanisms of down-regulation of Smad4 in TGF-β family signaling pathways during the tumorigenesis and aggressiveness of NB warrant further investigation.
Methods
Cell culture. Human NB cell lines SK-N-AS (CRL-2137), SH-SY5Y (CRL-2266), SK-N-SH (HTB-11), SK-N-BE(2) (CRL-2271), NB-1643, BE(2)-C (CRL-2268), and IMR32 (CCL-127), and human endothelial cell line HUVEC (CRL-1730) were purchased from American Type Culture Collection (Rockville, MD) and Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cell lines were authenticated by the provider, used within 6 months after resuscitation of frozen aliquots, and grown in RPMI1640 medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (Life Technologies, Inc.), penicillin (100 U/ml) and streptomycin (100 μ g/ml). Cells were maintained at 37 °C in a humidified atmosphere of 5% CO 2 , and applied for transfection or treatment with TGF-β protein, LY364947, BMP-2 protein, LDN-193189 (Sigma, St. Louis, MO), or activin A-neutralizing antibody (R&D Systems Inc., Minneapolis, MN) as indicated.
Gene over-expression and knockdown. Human Smad4 cDNA (1659 bp) was provided by Dr. Anna Coppa 43 and subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA) with primer indicated in Supplementary Table S3 . The 6Myc-tagged truncates and FLAG-tagged construct of Smad4 were provided by Dr. Ralf Janknecht 44 and Dr. Caroline S. Hill 45 , respectively. The Smad4 mutant constructs (D351H and R361H) were generated with GeneTailor TM Site-Directed Mutagenesis System (Invitrogen) and PCR primers (Supplementary Table S3 ). Human HPSE cDNA (1632 bp) and LEF1 cDNA (1200 bp) were amplified from NB tissue (Supplementary Table S3) , and subcloned into pcDNA3.1 (Invitrogen) and pCMV-3Tag-1A (Addgene, Cambridge, MA), respectively. The empty vector (mock) and Smad4 or HPSE constructs were transfected into tumor cells, and stable cell lines were screened by administration of neomycin or puromycin (Invitrogen). The mock-transfected cells were applied as controls. To restore the Smad4-induced down-regulation of HPSE, stable cell lines were transfected with the recombinant vector pcDNA3.1-HPSE or pCMV-3Tag-1A-LEF1. The oligonucleotides encoding shRNA specific for Smad4 or PPARG, and their scramble sequences were subcloned into GV102 (Genechem Co., Ltd, Shanghai, China; Supplementary Table S3) , and transfected into tumor cells with Genesilencer Transfection Reagent (Genlantis, San Diego, CA).
Luciferase reporter assay. Human HPSE promoter luciferase reporter constructs were kindly provided by Dr. Xiulong Xu (Rush University Medical Center) 16, 17, 46, 47 . The TCF/LEF-responsive reporter (TOP-FLASH and FOP-FLASH), Smad4 response element reporter (pSBE4-Luc), and BMP/Smad transcriptional reporter (pGL3-BRE-Luc) plasmids were obtained from Millipore (Billerica, MA) and Addgene, respectively. Mutation of Smad4 or LEF1 binding site was performed with GeneTailor TM Site-Directed Mutagenesis System (Invitrogen) and PCR primers (Supplementary Table S3 ). Dual-luciferase assay was performed as previously described 16, 17, 46, 47 .
Nuclear run-on assay. Nuclear run-on assay was performed based on the incorporation of biotin-16-uridine-5'-triphosphate into nascent transcripts as previously described 16, 17, 48, 49 . Total RNA was extracted using Trizol (Invitrogen), and biotinylated nascent RNA was purified using agarose-conjugated streptavidin beads (Invitrogen). Beads were then eluted, and biotinylated RNA was isolated for real-time quantitative RT-PCR assay with primers (Supplementary Table S4 ).
Western blot. Tissue or cellular protein was extracted with 1× cell lysis buffer (Promega, Madison, WI).
Western blot was performed as previously described 47, [50] [51] [52] [53] , with antibodies specific for Smad4, p-Smad1, p-Smad2, LEF1, HPSE, H3 histone, and β -actin (Santa Cruz Biotechnology, Santa Cruz, CA). ECL substrate kit (Amersham, Piscataway, NJ) was used for the chemiluminscent detection of signals with autoradiography film (Amersham).
Real-time quantitative RT-PCR.
Total RNA was isolated with RNeasy Mini Kit (Qiagen Inc., Valencia, CA). The reverse transcription reactions were conducted with Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN). Real-time PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and primers indicated in Supplementary Table S4 . The transcript levels were analyzed by 2 −△△Ct method.
Co-immunoprecipitation.
Co-IP was performed as previously described 16 , with antibodies specific for Smad4, LEF1, Myc, and FLAG (Upstate Biotechnology, Temacula, CA). The bead-bound proteins were released by boiling the protein A-Sepharose beads (Santa Cruz Biotechnology) in 1 × SDS-PAGE loading buffer and analyzed by western blot.
Chromatin immunoprecipitation.
ChIP assay was performed according to the manufacture's instructions of EZ-ChIP kit (Upstate Biotechnology) 16, 54, 55 . DNA was sonicated into fragments of an average size of 200 bp. Different sets of PCR primers were designed, targeting the Smad4 and LEF1 binding site within HPSE promoter (Supplementary Table S4 ). Real-time qPCR with SYBR Green PCR Master Mix was performed using ABI Prism 7700 Sequence Detector.
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Cell viability assay. Tumor cells were cultured in 96-well plates at 5 × 10 3 cells per well. Cell viability was monitored by the 2-(4,5-dimethyltriazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) colorimetric assay 16, 55 . All experiments were done with 6-8 wells per experiment and repeated at least three times.
Soft agar assay. Tumor cells at 5 × 10 3 were mixed with 0.05% Nobel agar (Fisher Scientific, Pittsburgh, PA) in growth medium and plated onto 6-well plates containing a solidified bottom layer (0.1% Noble agar in growth medium). After the incubation of cells for 21 days, the number of cell colonies was counted under the microscope, and the cells were fixed with 100% methanol and stained with 0.5% crystal violet dye 50, 54 .
Cell invasion assay. Matrigel invasion assay was performed using membranes coated with Matrigel matrix (BD Science, Sparks, MD). Homogeneous single cell suspensions (1 × 10 5 cells/well) were added to the upper chambers and allowed to invade for 24 hrs at 37 °C in a CO 2 incubator. Invaded cells were stained with 0.1% crystal violet for 10 min at room temperature and examined by light microscopy. Quantification of invaded cells was performed according to published criteria 47, [50] [51] [52] 55, 58 .
Tube formation assay. Fifty microliters of growth factor-reduced matrigel were polymerized on 96-well plates. HUVECs were serum starved in RPMI1640 medium for 24 hrs, suspended in RPMI1640 medium preconditioned with tumor cells, added to the matrigel-coated wells at the density of 5 × 10 4 cells/well, and incubated at 37 °C for 18 hrs. Quantification of angiogenic activity was calculated by measuring the length of tube walls formed between discrete endothelial cells in each well relative to the control 17, 48, 49, 51, 55 .
Immunofluorescence assay. Tumor cells were plated on coverslips, permeabilized with 0.3% Triton X-100, and blocked with 5% milk for 1 hr. Cells were incubated at 4 °C overnight with antibodies specific for Smad4 or LEF1 (Santa Cruz Biotechnology; 1:200 dilutions). Then, cells were incubated with Alexa Fluor 594 goat anti-rabbit IgG (1:1000 dilution), stained with 4′,6-diamidino-2-phenylindole (DAPI, 300 nmol/L) to visualize nuclei, and photographed under a microscope.
In vivo growth, metastasis and angiogenesis assay. All Immunohistochemistry. Immunohistochemical staining was performed as previously described 47, 50, 54, 58 
Statistical analysis.
Unless otherwise stated, all data were shown as mean ± standard error of the mean (SEM). The χ 2 analysis and Fisher exact probability analysis were applied for comparison among the gene expression and individual clinicopathological features. Pearson's coefficient correlation was applied for analyzing the relationship among gene expression. The Kaplan-Meier method was used to estimate survival rates. Difference of tumor cells was determined by t test or analysis of variance (ANOVA).
